… associated with the progression from mild to moderate COVID-19 illness to severe or critical
… on the pharmacologic treatment of patients with early COVID-19 (mild to moderate stages) …

… drugs for treating COVID-19. In the present review, the drug candidates that have been
suggested to treat COVID-… majority of patients present with mild symptoms and a good prognosis. …

… Here, we discuss the presentation and management of Covid-19 in patients with mild or
moderate illness, as well as prevention and control of the infection. Discussion of Covid-19 that …

… hospitalized with moderate COVID-19 are lacking. We consider that pregnant women with
moderate COVID-19 are at risk for worsening illness if not hospitalized and treated promptly. …

… in the treatment of early mild or moderate Covid-19 in a cohort of … Covid-19 because of
preexisting medical conditions. We assessed the effect of early intervention with antibody therapy …

… Molnupiravir, an orally administered drug, has recently been approved at least in the United
Kingdom and the United States for use in patients with mild to moderate COVID-19. It is a …

… Only 29% of current evidence on pharmacological management of COVID-19 is on
moderate/high evidence certainty and can therefore be confidently incorporated into practice and …

… Favipiravir is an established drug for the treatment of influenza and is being explored … the
treatment of COVID-19. It is the first oral antiviral drug approved for mild to moderate COVID-19. …

… the effect of bamlanivimab alone or in combination with etesevimab in reducing the risk of
disease progression or mortality in patients with mild COVID-19 compared with no treatment? …

… COVID-19, particularly in patients with moderate to severe COVID-19, the classes of drugs
used are antiviral agents, inflammation inhibitors/antirheumatic drugs, low molecular weight …